CNXBEarnings•globenewswire•
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
Sentiment:Negative (20)
Summary
– Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations –
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 13, 2025 by globenewswire